Baillie Gifford & CO Cellectis S.A. Transaction History

Baillie Gifford & CO

$126 Billion
Q1 2024

A detailed history of Baillie Gifford & CO transactions in Cellectis S.A. stock. As of the latest transaction made, Baillie Gifford & CO holds 827,248 shares of CLLS stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

827,248

Previous 816,643 1.3%

Holding current value

$1.57 Million

Previous $2.52 Million 12.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$2.41 - $3.09 $25,558 - $32,769	10,605 Added 1.3%	827,248 $2.19 Million
Q4 2023 Jan 26, 2024	SELL	$0.97 - $3.55 $336,945 - $1.23 Million	-347,366 Reduced 29.84%	816,643 $2.52 Million
Q3 2023 Nov 13, 2023	SELL	$1.58 - $2.86 $402,879 - $729,262	-254,987 Reduced 17.97%	1,164,009 $1.84 Million
Q2 2023 Jul 28, 2023	SELL	$1.72 - $2.12 $379,948 - $468,308	-220,900 Reduced 13.47%	1,418,996 $2.8 Million
Q1 2023 May 03, 2023	BUY	$1.83 - $3.84 $1.9 Million - $3.99 Million	1,040,000 Added 173.36%	1,639,896 $3.16 Million

Q4 2022 Jan 24, 2023	SELL	$1.85 - $2.53 $349,540 - $478,020	-188,941 Reduced 23.95%	599,896 $1.26 Million
Q3 2022 Oct 27, 2022	SELL	$2.42 - $4.08 $222,869 - $375,747	-92,095 Reduced 10.45%	788,837 $1.81 Million
Q2 2022 Aug 08, 2022	SELL	$2.39 - $4.93 $480,779 - $991,733	-201,163 Reduced 18.59%	880,932 $2.49 Million
Q1 2022 May 05, 2022	BUY	$3.45 - $8.77 $8,914 - $22,661	2,584 Added 0.24%	1,082,095 $4.91 Million
Q4 2021 Jan 20, 2022	BUY	$8.01 - $12.84 $23,917 - $38,340	2,986 Added 0.28%	1,079,511 $8.77 Million
Q3 2021 Oct 19, 2021	BUY	$11.94 - $16.09 $509,276 - $686,286	42,653 Added 4.13%	1,076,525 $13.6 Million
Q2 2021 Aug 02, 2021	BUY	$14.36 - $20.93 $14.8 Million - $21.6 Million	1,033,872 New	1,033,872 $16 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

9.83M

Call Options Held

Put Options Held

30.9K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86.5M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Cellectis S.A. Transaction History